Phathom Pharmaceuticals PHAT 深 滬
等待開盤 07-18 09:30:00 美东时间
8.32
-0.010
-0.12%
華盛通- 最 高8.65
- 今 開8.33
- 成交量 86.29万股
- 最 低 8.07
- 昨 收 8.33
- 總市值 5.81亿
- 52周最高 19.71
- 市盈率 靜 --
- 換手率 1.24%
- 52周最低 2.21
- 委 比 36.75%
- 總股本 6981.41万
- 歷史最高 64.54
- 量 比 0.96
- 振 幅 6.96%
- 歷史最低 2.21
- 每 手 1
- 風險率 3.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Phathom Pharmaceuticals has granted inducement awards to Anne Marie Cook upon her appointment as Chief Legal Officer and Corporate Secretary. The awards include non-qualified stock options for 210,000 shares, vesting over four years, and performance-based stock units tied to financial goals over three years, under the 2025 Inducement Plan. Phathom specializes in novel treatments for gastrointestinal diseases and markets vonoprazan-based products,...
06-23 20:15
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
Phathom Pharmaceuticals announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary. With extensive experience in the pharmaceutical industry, Cook brings expertise in corporate governance, regulatory compliance, and strategic transactions. She previously held senior legal roles at Sage Therapeutics, Aegerion Pharmaceuticals, and Biogen. Cook expressed enthusiasm for contributing to Phathom's growth in gastr...
06-23 11:59
Phathom says FDA confirmed Voqueza exclusivity through May 2032
Phathom Pharmaceuticals (NASDAQ:PHAT) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezna (vonoprazan) new chemical entity exclusivity is valid through May 3, 2032. The exclu...
06-16 21:13
Phathom Pharmaceuticals Gains FDA Exclusivity for VOQUEZNA
Phathom Pharmaceuticals ( ($PHAT) ) has provided an update. On June 16, 2025, P...
06-16 20:28
美股大行评级 | eToro Group获多家大行首予买入评级，甲骨文获多家机构上调目标价
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持PolyPid(PYPD)"买入"评级，目标价从11美元升至13美元</p> <p>• HC Wainwright & Co.：维持Vertical Aerosp
06-10 09:45
美股大行评级 | 潜在涨幅925.64%！Aemetis获Ascendiant Capital升目标价至20美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1138028221594226688.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持Aemetis(AMTX)"买入"评级，目标价从19美元升至20美元</p> <p>• Ascendiant Capital：维持Lucid Diagnostics(LUCD)"买
06-07 08:37
Phathom Pharmaceuticals Gains FDA Approval for VOQUEZNA® Exclusivity
Phathom Pharmaceuticals ( ($PHAT) ) has provided an announcement. On June 6, 20...
06-07 04:57
Needham Maintains Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Needham analyst Joseph Stringer maintains Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $28 price target.
06-07 02:44
UPDATE: Watching Phathom Pharmaceuticals; Shares Spike Higher, FDA Has Granted The Co The 10 Year NCE Exclusivity And The Correction To The Orange Book Listings For 10 Mg & 20 Mg Voquezna Tablets To Reflect Full 10-Year NCE Exclusivity Through May 3, 2032
https://downloads.regulations.gov/FDA-2024-P-5703-0013/attachment_1.pdf
06-06 23:49
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
Phathom Pharmaceuticals announced that the FDA has approved its Citizen Petition, extending the exclusivity period for VOQUEZNA (vonoprazan) tablets through May 3, 2032, recognizing 10 years of New Chemical Entity exclusivity. VOQUEZNA is a first-in-class potassium-competitive acid blocker (PCAB) approved for treating heartburn, GERD, and H. pylori infection. The approval signals the correction of the Orange Book listing and reinforces Phathom's ...
06-06 16:27
